Vioxx Research Today is a free monthly online journal that collates and summarizes the latest research about Vioxx, including details on osteoarthritis, side-effects, trials, stroke, heart attack.

Volume 5 (2008), Issue 4 (April)

1. Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction?
   Nat Clin Pract Rheumatol, 4(4): 182-3. [Abstract] [Full-text]
2. Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma.
   Nat Clin Pract Rheumatol, 4(4): 218-21. [Abstract] [Full-text]
3. Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors.
   Bioorg Med Chem, 16(7): 3907-16. [Abstract] [Full-text]
4. Rofecoxib potentiates the anticonvulsant effect of topiramate.
   Inflammopharmacology, 16(2): 83-6. [Abstract] [Full-text]
5. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.
   JAMA, 299(15): 1813-7. [Abstract] [Full-text]
6. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.
   JAMA, 299(15): 1800-12. [Abstract] [Full-text]
7. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal.
   Arthritis Rheum, 59(4): 568-74. [Abstract] [Full-text]
8. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition.
   Circ Res, 102(8): 986-93. [Abstract] [Full-text]

© 2004-2008 Vioxx Research Today. All Rights Reserved.